Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verrica Pharmaceuticals reports strong Q3 revenue growth and promising therapies

Verrica Pharmaceuticals' Q3 performance reflects strong revenue generation from YCANTH and promising developments in novel therapies like VP-315.
While facing challenges in market clearance efforts and significant SG&A costs, the company's strategic initiatives position it for future growth.
Opportunities lie in expanding market presence, optimizing costs, and protecting intellectual property to drive profitability and innovation.

Verrica Pharmaceuticals reports robust Q4 earnings and eyes regulatory milestones

Verrica Pharmaceuticals showcased strong financial performance with $1.9 million in YCANTH net revenue and 94% gross margins for 2023.
Strategic partnerships, pipeline advancements, and progress in eliminating market challenges position the company for future growth.
Challenges in sampling activity, revenue forecasting, and regulatory uncertainties require careful navigation for sustained success.
Opportunities in distribution expansion, revenue optimization, and regulatory advancements offer avenues for continued development and success.

Verrica Pharmaceuticals excels in Q1 with strong revenue growth

Verrica Pharmaceuticals demonstrated strong performance in Q1 2024 with significant revenue generation and pipeline advancements.
While facing financial challenges and uncertainties, the company's strategic strengths and opportunities position it well for future growth.
Addressing cost management, market integrity, and maximizing revenue potential will be crucial for sustaining profitability and market leadership.

Verrica Pharmaceuticals excels in Q2, eyes market expansion opportunities

Verrica Pharmaceuticals' Q2 performance reflects strong revenue growth and promising developments in product pipelines. While challenges exist in accelerating demand and maintaining profitability, the company's strategic focus on partnerships and market optimization positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)

Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks

Athersys

Amicus Therapeutics

Lexicon Pharmaceuticals

Moderna

Nanobiotix SA

United Therapeutics

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts for May

Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum

Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results

WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022 at 3:00 p.m. ET.

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

LTX-315's novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate in a fireside chat at the 42nd Annual Cowen Virtual Healthcare Conference on Wednesday, March 9, 2022, at 11:10 a.m. ET.

Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference

The FDA has accepted Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (molluscum), a common, highly contagious skin disease. The assigned Prescription Drug User Fee Act (PDUFA) goal date is May 24, 2022.

FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease

WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) acknowledged that Verrica's resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) was complete and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022.

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA).

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility's identified deficiencies from the FDA

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?

NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Verrica Pharmaceuticals Inc. -VRCA

The Food and Drug Administration delivered some bad news regarding the company's dermatology candidate.

Why Verrica Pharmaceuticals Stock Is Getting Pummeled Today

Verrica Pharmaceuticals (NASDAQ:VRCA) shares are trading lower after the company announced the FDA issued a Complete Response Letter regarding its New Drug Application for VP-102 for the treatment of molluscum contagiosum. Verrica Pharmaceuticals' stock has been falling Tuesday, down 16.37% to a price of $10.06.

Why Verrica Pharmaceuticals Shares Are Trading Lower Today

The stock price of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) fell by over 15% during intraday trading today. This is why it happened.

VRCA Stock: Why It Significantly Decreased Today

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagious viral skin disease. The FDA had previously extended the Prescription Drug User Fee Act (PDUFA) goal date for the application by three months.

Verrica Pharma Shares Slide After Response Letter From FDA

No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021.

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

Company strengthens management team in anticipation of  the potential commercial launch of VP-102, if approved

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

News for Verrica Pharmaceuticals Inc Stock (VRCA)